DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 022348
NDA 022348 describes CALDOLOR, which is a drug marketed by Cumberland Pharms and is included in one NDA. It is available from one supplier. There are eight patents protecting this drug. Additional details are available on the CALDOLOR profile page.
The generic ingredient in CALDOLOR is ibuprofen. There are sixty-four drug master file entries for this compound. Two hundred and forty-six suppliers are listed for this compound. Additional details are available on the ibuprofen profile page.
The generic ingredient in CALDOLOR is ibuprofen. There are sixty-four drug master file entries for this compound. Two hundred and forty-six suppliers are listed for this compound. Additional details are available on the ibuprofen profile page.
Summary for 022348
| Tradename: | CALDOLOR |
| Applicant: | Cumberland Pharms |
| Ingredient: | ibuprofen |
| Patents: | 8 |
| Therapeutic Class: | Analgesics Anti-inflammatory Agents |
| Formulation / Manufacturing: | see details |
Pharmacology for NDA: 022348
| Ingredient-type | Nonsteroidal Anti-inflammatory Compounds |
| Mechanism of Action | Cyclooxygenase Inhibitors |
Medical Subject Heading (MeSH) Categories for 022348
Suppliers and Packaging for NDA: 022348
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CALDOLOR | ibuprofen | SOLUTION;INTRAVENOUS | 022348 | NDA | Cumberland Pharmaceuticals Inc. | 66220-287 | N | 66220-287-08 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;INTRAVENOUS | Strength | 400MG/4ML (100MG/ML) | ||||
| Approval Date: | Jun 11, 2009 | TE: | RLD: | No | |||||
| Patent: | ➤ Try a Free Trial | Patent Expiration: | Nov 27, 2021 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY | ||||||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 800MG/8ML (100MG/ML) | ||||
| Approval Date: | Jun 11, 2009 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Nov 20, 2018 | ||||||||
| Regulatory Exclusivity Use: | DOSING RECOMMENDATIONS AS NECESSARY FOR FEVER AND PAIN FOR AGES 6MO TO LESS THAN 12 YEARS AND 12 TO 17 YEARS. | ||||||||
| Regulatory Exclusivity Expiration: | Nov 20, 2018 | ||||||||
| Regulatory Exclusivity Use: | NEW PATIENT POPULATION | ||||||||
Complete Access Available with Subscription
